Claudin-18.2

Claudin-18.2

Claudin-18.2 Overview

Molecule Name
Claudin-18 splice variant 2
Synonyms
Claudin-18.2,CLDN18,Claudin-18
Drug Development Progress
Drugs in Clinical Trials85
Approved Drugs1
Highest Development StageApproved
Target Synonym
UNQ778/PRO1572,CLDN18,Claudin 18,Surfactant Associated Protein J,Surfactant, Pulmonary Associated Protein J,Surfactant Associated 5,Claudin-18,SFTA5,SFTPJ,Claudin 18.2,CLDN18.2
Background
Claudins (CLDNs) are a family of proteins that form tight junctions and maintain the polarity of epithelial and endothelial cells. CLDN18 is specifically expressed in the stomach and lung. Of the two CLDN18 isoform transcripts produced by alternative splicing, CLDN18.2 is a highly selective gastric lineage marker that determines the gastric phenotype in a neoplastic condition, whereas CLDN18.1 is lung specific. CLDN18.2 is a highly selective gastric lineage antigen expressed exclusively on short-lived differentiated gastric epithelial cells where it has only limited accessibility to antibody drugs.14,15 CLDN18.2 is maintained during the course of malignant transformation and thus frequently displayed on the surface of human gastric cancer cells.

Claudin-18.2 Product List

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Antibody Project Trading Platform

Project NameProject StageMolecule TypeMolecule SourceDisease AreaIndication
CLDN18.2 CAR-T - 01PhaseICARNanobodySolid TumorAdvanced refractory gastrointestinal tumors
CLDN18.2 VHH - 01LeadMonoclonalNanobodySolid TumorGastric Cancer,Pancreatic cancer
Project Stage
PhaseI
Molecule Type
CAR
Molecule Source
Nanobody
Disease Area
Solid Tumor
Indication
Advanced refractory gastrointestinal tumors
Project Name
CLDN18.2 VHH - 01
Project Stage
Lead
Molecule Type
Monoclonal
Molecule Source
Nanobody
Disease Area
Solid Tumor
Indication
Gastric Cancer,Pancreatic cancer

Project Cooperation

Project NameDrug TypeTherapeutic AreaIndicationStageRights Area
Claudin18.2×CD8+ T bsAbBispecific antibodyOncology/CancerGastric cancer,Pancreatic cancer,OophoromaINDGlobal
CLDN 18.2 CAR-TCell therapyOncology/CancerGastric Cancer,Pancreatic CancerINDGlobal
Claudin18.2 mAbMonospecific antibodyOncology/CancerGastric cancerPhase IGlobal
Drug Type
Bispecific antibody
Therapeutic Area
Oncology/Cancer
Indication
Gastric cancer,Pancreatic cancer,Oophoroma
Stage
IND
Rights Area
Global
Project Name
CLDN 18.2 CAR-T
Drug Type
Cell therapy
Therapeutic Area
Oncology/Cancer
Indication
Gastric Cancer,Pancreatic Cancer
Stage
IND
Rights Area
Global
Project Name
Claudin18.2 mAb
Drug Type
Monospecific antibody
Therapeutic Area
Oncology/Cancer
Indication
Gastric cancer
Stage
Phase I
Rights Area
Global